Norway· NO-ID_E3D79D8F-71CD-4B61-AC0F-67D3CE63D1D8
Simponi
A golimumab product containing golimumab, registered in Norway by Janssen-Cilag International N.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Golimumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB06 (golimumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Golimumab · ATC L04AB06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Golimumab
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Norway (NO)
- ATC code
- L04AB06
- ATC class
- Golimumab
- Defined daily dose
- 1.66 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_E3D79D8F-71CD-4B61-AC0F-67D3CE63D1D8
- no_varenummer4322141NOK 11482.2
- gtin7323281005957
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
429 interactions on record for golimumab.
Graded by severity as the source publishes them — 287 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Golimumab · interactions on record
429 records
- 287 severe
- 135 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Golimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGOBIVAZADVANZ PHARMA Limited, Dublin
- United KingdomGobivaz 100mg/1ml solution for injection pre-filled pensAdvanz Pharma
- SwedenGOBIVAZ 100 mg Injektionsvätska, lösning i förfylld injektionspennaAdvanz Pharma Limited
- IcelandGobivazADVANZ PHARMA Limited
- BelgiumGobivaz 100 mgAdvanz Pharma
- PolandGobivazAdvanz Pharma Limited
- SpainGOBIVAZ 100 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAAdvanz Pharma Limited
- FinlandGobivazAdvanz Pharma Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Gotenfia
- Iceland · Gobivaz, Gotenfia
- Liechtenstein · Gobivaz, Gotenfia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d505fe44-90af-4df8-b444-8cf51694a5e0 GET /v1/drugs/d505fe44-90af-4df8-b444-8cf51694a5e0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning i ferdigfylt penn",
"source": "fest",
"status": "A",
"atc_name": "Golimumab",
"merkevare_id": "ID_E3D79D8F-71CD-4B61-AC0F-67D3CE63D1D8",
"name_form_strength": "Simponi inj, oppl 100 mg/penn",
"prescription_group": "C"
}See everything about golimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.